Rx Error Reduction May Need Reduced Prescriber Autonomy - Woodcock
Stricter prescribing regulations may be one way to reduce the number of preventable adverse drug events, FDA Center for Drug Evaluation & Research Director Janet Woodcock, MD, suggested Nov. 17.
You may also be interested in...
Reform of the pharmaceutical adverse event monitoring system must be based on a larger debate over the societal expectations for clinical research, Center for Drug Evaluation & Research Deputy Director Murray Lumpkin, MD, told a Drug Information Association/ General Accounting Office panel Feb. 24 in Washington, D.C.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials